title: [Successful rituximab therapy of HCV-cryoglobulinemic vasculitis with severe ulcerative and necrotic lesions of the skin].
abstract: This clinical observation demonstrates successful rituximab therapy of HCV-cryoglobulinemic vasculitis with severe ulcerative and necrotic lesions of the skin on the lower extremities. Vasculitis recurred 3 years after the persistent virological response had been achieved and complete clinical remission resulted from antiviral therapy. Possible causes of vasculitis relapses in the absence of HCV viremia are discussed with reference to the difficulties encountered in managing this condition.
authors.forename: T M
authors.initials: TM
authors.lastname: Ignatova
authors.forename: O A
authors.initials: OA
authors.lastname: Chernova
authors.forename: E V
authors.initials: EV
authors.lastname: Gaĭdasheva
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D005260:Female; D016174:Hepacivirus / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009336:Necrosis; D000069283:Rituximab; D012720:Severity of Illness Index; D012871:Skin Diseases / Q000209:etiology / Q000473:pathology*; D014456:Ulcer / Q000209:etiology / Q000473:pathology; D014657:Vasculitis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D000069283:Rituximab